Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för farglitazar. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2017-06-12

Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.

Pirat C, Dacquet C, Leclerc V, Hennuyer N, Beucher-Gaudin M, Zanirato G, Géant A, Staels B, Ktorza A, Farce A, Caignard DH, Berthelot P, Lebegue N.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.06.006

Bibliografisk träff 2011-11-28

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.

J Med Chem · journal article · DOI 10.1021/jm201061j

Bibliografisk träff 2010-04-14

Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).

Yamagishi K, Yamamoto K, Mochizuki Y, Nakano T, Yamada S, Tokiwa H.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2010.04.031

Bibliografisk träff 2007-03-18

QSAR analysis of PPAR-gamma agonists as anti-diabetic agents.

Dixit A, Saxena AK.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2007.03.004

Bibliografisk träff 2007-01-25

Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.

Devasthale PV, Chen S, Jeon Y, Qu F, Ryono DE, Wang W, Zhang H, Cheng L, Farrelly D, Golla R, Grover G, Ma Z, Moore L, Seethala R, Sun W, Doweyko AM, Chandrasena G, Sleph P, Hariharan N, Cheng PT.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2007.01.060

Bibliografisk träff 2006-09-26

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2006.09.028

Bibliografisk träff 2001-12-01

Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.

Liu KG, Lambert MH, Ayscue AH, Henke BR, Leesnitzer LM, Oliver WR, Plunket KD, Xu HE, Sternbach DD, Willson TM.

Bioorg Med Chem Lett · journal article · DOI 10.1016/s0960-894x(01)00649-7

Bibliografisk träff 2000-02-01

The PPARs: from orphan receptors to drug discovery.

Willson TM, Brown PJ, Sternbach DD, Henke BR.

J Med Chem · review; journal article · DOI 10.1021/jm990554g

Bibliografisk träff 1998-12-01

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM.

J Med Chem · journal article · DOI 10.1021/jm9804127

Bibliografisk träff 1998-12-01

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.

Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, Henke BR, Hull-Ryde EA, Kazmierski WM, Lake DH, Leesnitzer LM, Lehmann J, Lenhard JM, Orband-Miller LA, Gray-Nunez Y, Parks DJ, Plunkett KD, Tong WQ.

J Med Chem · journal article · DOI 10.1021/jm980413z

Bibliografisk träff 1998-12-01

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.

Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, Lake DH, Lenhard JM, Oliver W, Oplinger J, Pentti M, Parks DJ, Plunket KD, Tong WQ.

J Med Chem · journal article · DOI 10.1021/jm980414r